Search Results

NeuroRx, Inc. and TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) are announcing that the companies have entered into a feasibility and material transfer agreement (Feasibility Agreement).

The issues raised by Relief Therapeutics in its release dated April 19, 2021 have no bearing on NeuroRx’s ability or commitment to deliver a safe, effective, and stable lifesaving drug on a worldwide basis.

NeuroRx, Inc. and RELIEF THERAPEUTICS Holding AG, and the Quantum Leap Healthcare Collaborative of San Francisco announce that NeuroRx and QLHC have signed a Clinical Trial Participation Agreement for the inclusion of ZYESAMI™ in the I-SPY COVID-19 Clinical Trial.

Like many biopharma companies, the global COVID-19 pandemic has caused delays while also offering opportunities for NeuroRx.

NeuroRx, Inc. reports that Aviptadil, to be supplied by NeuroRx, has been identified by the National Institutes of Health as one of two drugs selected for inclusion in a phase III multicenter clinical trial that will include the United States and multiple foreign countries.

NeuroRx, Inc., a clinical-stage pharmaceutical company developing small molecules for unmet medical needs, announced that Chairman and CEO Jonathan C.

RELIEF THERAPEUTICS Holding AG, a biopharmaceutical company with its lead compound RLF-100 in advanced clinical development, announces that its partner, NeuroRx, Inc., has reported that work is underway to determine the feasibility of formulating RLF-100 as a dry powder using TFF Pharmaceuticals’ Thin-Film Freezing technology.